Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,641 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Disorder Clear all
Recruiting Phase 1 Interventional

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions
BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates

NCT01236781
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Screening Tomosynthesis, Diagnostic Tomosynthesis
Device
Lead sponsor
American College of Radiology
Other
Eligibility
25 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jul 23, 2026, 6:23 PM EDT
Recruiting Not applicable Interventional

Intravital Microscopy in Human Solid Tumors

NCT03823144
View directory record Official record
Conditions
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Primary Malignant Brain Neoplasm, Metastatic Sarcoma, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Resectable Colorectal Carcinoma, Resectable Liver and Intrahepatic Bile Duct Carcinoma, Resectable Pancreatic Carcinoma, Resectable Sarcoma, Stage IV Colorectal Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Brain Neoplasm, Metastatic Breast Carcinoma, Metastatic Liver Carcinoma, Metastatic Pancreatic Carcinoma, Resectable Brain Neoplasm, Resectable Breast Carcinoma, Resectable Gastric Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

NCT00037609
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
Capecitabine, Exisulind
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Jul 23, 2026, 6:23 PM EDT
Recruiting No phase listed Observational

Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction

NCT07546331
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer
Interventions
Measurement of Body Composition, Chart Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

NCT00365365
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab, Bevacizumab and trastuzumab maintenance therapy, Bevacizumab maintenance therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Not applicable Interventional

Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer

NCT04493034
View directory record Official record
Conditions
Breast Cancer
Interventions
Art Therapy, Music Therapy
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 23, 2026, 6:23 PM EDT
Recruiting Phase 3 Interventional

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
85
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Bundled Cancer Screening and Genetic Services Navigation

NCT07228000
View directory record Official record
Conditions
Breast Cancer Screening, Colon Cancer Screening, Genetics Predisposition
Interventions
Breast cancer screening navigation, Multicancer screening navigation, Usual care genetics referral, Pretest education + usual care genetics referral
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
45 Years to 74 Years · Female only
Enrollment
820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Newark, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Phase 3 Interventional

Docetaxel in Treating Patients With Metastatic Breast Cancer

NCT00008411
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 23, 2026, 6:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

NCT03546972
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity, Overweight, Premalignant Lesion
Interventions
Behavioral, Psychological or Informational Intervention, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jul 23, 2026, 6:23 PM EDT
Completed No phase listed Observational

Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors

NCT00872677
View directory record Official record
Conditions
Breast Cancer, Obesity, Weight Changes
Interventions
Diet, Spiritual counseling
Behavioral · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Jul 23, 2026, 6:23 PM EDT
Completed No phase listed Observational

Quantitative Dynamic Contrast Enhanced Breast MRI

NCT00582764
View directory record Official record
Conditions
Breast Cancer
Interventions
perform dynamic contrast enhanced (DCE) MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Jul 23, 2026, 6:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tumor-Derived FGF19

NCT06068257
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Healthy
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Treatment of Breast Cancer

NCT00254592
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Carboplatin, Nab-paclitaxel, GM-CSF, Trastuzumab, Bevacizumab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Jul 23, 2026, 6:23 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

NCT05035836
View directory record Official record
Conditions
Breast Cancer, HER2-positive
Interventions
Zanidatamab, Letrozole, Tamoxifen
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Not applicable Interventional

Soy-Based Meal Replacement in Helping Women With Stage I, Stage II, or Stage III Breast Cancer in Complete Remission Lose Weight

NCT00343434
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
behavioral dietary intervention, exercise intervention, soy isoflavones, soy protein isolate, counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jul 23, 2026, 6:23 PM EDT
Recruiting No phase listed Observational

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Recruiting Phase 1 Interventional

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 6:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Intervention Study for Better Breast and Cervical Cancer Control for Korean American Women

NCT00857636
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
Health literacy, health message
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Ellicott City, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Jul 23, 2026, 6:23 PM EDT
Terminated Phase 1Phase 2 Interventional

ABI-008 Trial in Patients With Metastatic Breast Cancer

NCT00531271
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABI-008 (nab-docetaxel)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jul 23, 2026, 6:23 PM EDT
Terminated Phase 1 Interventional

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT01552434
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 6:23 PM EDT